Author

Fu Chung Hsiao

The University of Texas MD Anderson Cancer Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:metabolomics· 2 Assay:proteomics· 2

Frequent Co-Authors

Ehsan IrajizadiD· 3 shared Hiroyuki KatayamaiD· 3 shared Jennifer B. DennisoniD· 3 shared Jody Vykoukal· 3 shared Johannes Francois FahrmanniD· 3 shared Ricardo A. Léon-LetelieriD· 3 shared Samir HanashiD· 3 shared Yining Cai· 3 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Ehsan IrajizadORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma

Yihui Chen, Cason Haffner, Benson Chellakkan Selvanesan, Ranran Wu, Riccardo Ballarò, Ana Vilchis Celis, Mingxin Zuo, LaNisha L. Patterson, Michael Adofo, Jody Vykoukal, Ricardo A. Léon-Letelier, Rongzhang Dou, Soyoung Park, Yining Cai, Daniela Rodriguez-Perera, , Johannes Francois Fahrmann

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

bioRxiv · Oct 6, 2026 · PreprintCancer Biology

Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer

Jody Vykoukal, Yihui Chen, Mingxin Zuo, Riccardo Ballarò, M. J. Hong, H. Krishna, Daniela Rodriguez-Perera, Hiroyuki Katayama, Ehsan Irajizad, Ranran Wu, Ricardo A. Léon-Letelier, Jennifer B. Dennison, Angelica M. Gutierrez‐Barrera, Adriana A. Paulucci-Holthauzen, Timothy C. Thompson, , Johannes Francois Fahrmann

The paper identifies a metabolic vulnerability in triple-negative breast cancer through sphingolipid metabolism, showing that targeting this pathway with eliglustat reduces tumor growth and improves survival.

Cell Reports Medicine · Dec 1, 2025Peer-reviewedCancer Biology

Aberrant expression of CD14 in breast tumor cells is associated with poor outcome

Hiroyuki Katayama, Rongzhang Dou, Ricardo A. Léon-Letelier, Ehsan Irajizad, Alejandro M. Sevillano, So‐Young Park, Fu Chung Hsiao, Yining Cai, Jody Vykoukal, Johannes Francois Fahrmann, Jennifer B. Dennison, Elizve Barrientos-Toro, Maria Gabriela Raso, Ayşegül Şahin, Samir Hanash

This study identifies aberrant CD14 expression in breast tumor cells as a marker of poor clinical outcomes and aggressive disease.

bioRxiv · Nov 7, 2024 · PreprintCancer Biology